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Background: Many publicly-funded health systems apply cost-benefit frameworks in response to the moral dilemma
of how best to allocate scarce healthcare resources. However, implementation of recommendations based on costs
and benefit calculations and subsequent challenges have led to ‘special cases’ with certain types of health benefits
considered more valuable than others. Recent debate and research has focused on the relative value of life extensions
for people with terminal illnesses. This research investigates societal perspectives in relation to this issue, in the UK.
Methods: Q methodology was used to elicit societal perspectives from a purposively selected sample of data-rich
respondents. Participants ranked 49 statements of opinion (developed for this study), onto a grid, according to
level of agreement. These ‘Q sorts’ were followed by brief interviews. Factor analysis was used to identify shared
points of view (patterns of similarity between individuals’ Q sorts).
Results: Analysis produced a three factor solution. These rich, shared accounts can be broadly summarised as:
i) ‘A population perspective – value for money, no special cases’, ii) ‘Life is precious – valuing life-extension and
patient choice’, iii) ‘Valuing wider benefits and opportunity cost - the quality of life and death’.
From the factor descriptions it is clear that the main philosophical positions that have long dominated debates
on the just allocation of resources have a basis in public opinion.
Conclusions: The existence of certain moral positions in the views of society does not ethically imply, and
pragmatically cannot mean, that all are translated into policy. Our findings highlight normative tensions and
the importance of critically engaging with these normative issues (in addition to the current focus on a
procedural justice approach to health policy). Future research should focus on i) the extent to which these
perspectives are supported in society, ii) how respondents' perspectives relate to specific resource allocation
questions, and iii) the characteristics of respondents associated with each perspective.
Keywords: Social values, Life extension, Terminal illness, Societal perspectives, Health policy, Ethics, Resource
allocation, Q methodologyBackground
All health systems face the same fundamental, moral
dilemma: given that healthcare resources are scarce in
relation to demand for them, how should they be allo-
cated? This moral dilemma is also the defining social
problem of the discipline of health economics. As* Correspondence: neil.mchugh@gcu.ac.uk
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generally, produce an increasingly ‘high-tech’, high cost
range of available goods and services, and as pressure
on public funding increases, debates about the fairness
of healthcare provision have played out in the media as
well as in academic and policy circlesa. National health
technology assessment agencies have proliferated, inter-
nationally, to evaluate the costs and benefits of medicines
(and other technologies) and to make recommendations
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ogy assessment agencies have adopted a cost-utility frame-
work for the economic evaluation of health technologies;
typically operationalised as a cost per quality-adjusted life
year (QALY) approach. The principles underlying that
framework are related to opportunity cost and value for
money. Technologies that produce more units of health
per unit of cost are preferred to technologies that are less
effective and less efficient. All else equal, patients with
greater capacity to benefit will be prioritised over patients
who will benefit less. This has distributional consequences
and the issue of ‘special cases’ or, in other words, the
question of when some health benefits are considered
of greater value than others, has been debated for as
long as health economists have been assessing costs
and benefits. Many researchers have employed preference
elicitation techniques to measure societal values with re-
spect to different types of health gains arising to different
groups of others [1,2]. Most recently, debate and research
activities in this area have centred on the relative value of
life-extending medicines for people with terminal illness
(see for example the special issue of Health Economics
Policy and Law [3]).
A handful of empirical studies have contributed to an
evidence base around societal values on the topic, with a
focus on whether there is a positive, end of life ‘premium’
or ‘QALY weight’ that would imply that health gains for
people with terminal illnesses are associated with higher
societal value than health gains benefiting other groups of
patientsc. The evidence, however, remains limited and
equivocal. Shah et al. [4], Olsen [5] and Linley and Hughes
[6] find no, or limited, support for an end of life premium.
In contrast, Pinto-Prades et al. [7], Pennington et al. [8],
Shah et al. [9] and Rowen et al. [10] find evidence suggest-
ive of an end of life premium. These studies have taken
quantitative approaches, including discrete choice survey
methods [4,10], person or benefit trade-off questions [6,7]
and willingness to pay (WTP) [7,8].
The nature of the empirical evidence highlights the need
for further research investigating societal views around the
relative value of end of life treatments for patients with a
terminal illness. To date most studies have taken quantita-
tive, choice-based or equivalence (matching) approaches
to preference elicitation. In these studies, scenarios are
constructed on the basis of a restricted number of attri-
butes and present an artificial, controlled version of the
issues at stake. Such reductionism is appropriate and
necessary in studies that attempt to isolate the relative
impact of a specific set of attributes on respondents’
choices. The range of different methods applied may
partially explain the conflicting findings between studies
but in-depth, qualitative exploration could provide richer
insights into the reasons for disparities. Qualitative re-
search may even suggest a wider set of relevant attributesthan hitherto considered in quantitative studies. However,
to date, qualitative studies tend to be used only as a pre-
cursor to (or extended pilot test of) surveys and there has
not been an in-depth study.
In this study we use Q methodological techniques to
investigate the nature of UK societal perspectives in rela-
tion to the relative value of life extensions for people
with terminal illnesses.
The UK context
According to the National Institute for Health and Care
Excellence (NICE) decisions on the appropriate allocation
of resources are based on scientific judgments, supported
by legal considerations and, importantly for this research,
social value judgments [11]. NICE social value judgments
are grounded in the views of the general public, garnered
mainly through the work of the Citizens Councild, and
represented in a set of principles articulated in a docu-
ment which was originally issued by NICE in 2005, with a
second edition in 2008, and currently under revision again
[12,13]. In their social value judgment document, existing
debates on utilitarian and egalitarian approaches to dis-
tributive justice are mentioned in brief but NICE places
emphasis largely on procedural justice, based on Daniels
and Sabin’s [14] ‘accountability for reasonableness’. Des-
pite the emphasis given to procedural justice or ‘process
values’ [15], the cost per QALY calculatione appears to re-
main central to NICE recommendations [16].
In 2009 NICE issued supplementary guidance for the
appraisal of life-extending, end of life treatments [17] set-
ting out criteria which permit such treatments to be rec-
ommended, even if they are not cost-effective according
to the usual threshold applied.
NICE Supplementary Guidance for End of Life Treatments
Treatments for terminal illnesses are non-curative by
definition and so are likely to result in relatively small
health gains when compared to other types of treatment.
Such health gains often come at high cost and hence
medicines of this type are less likely to meet NICE’s
cost-effectiveness threshold. NICE technology appraisals
rejecting a number of end stage cancer drugs, on the
grounds of cost-effectiveness, were challenged and debates
culminated in the Richards Report “Improving access to
medicines for NHS patients” [18]. In response NICE is-
sued their supplementary guidance for the appraisal of
life-extending, end of life treatments [19]. This stipulates
that such treatments may be recommended if all of the
following criteria are met:
– “The treatment is indicated for patients with a short
life expectancy, normally less than 24 months and;
– There is sufficient evidence to indicate that the
treatment offers an extension to life, normally of at
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NHS treatment, and;
– The treatment is licensed or otherwise indicated, for
small patient populations” [17].
In a review of decisions following implementation of the
supplementary guidance, Longson and Littlejohns [20]
found that the NICE Appraisal Committee had recom-
mended treatments at a cost per QALY which implied a
QALY weight of 1.7 for life-extending, end of life treat-
ments. On the basis of appraisal decisions between 2009
and 2011, Collins and Latimer [21] estimated that between
5,933 and 15,098 QALYs were displaced by the provision
of end of life medicines (depending on application of a
cost per QALY threshold of £30,000 or £20,000). The
cost was estimated to be approximately £549 million a
year, calculated using estimates of patient populations
and incremental costs of treatment.
The Richards Report found a general view among
stakeholdersf that “drugs to treat patients in the last
months or years of life should be regarded as having a
very high priority” ([18], p42). Of 29 NICE Citizen
Council members, 10 thought it was acceptable to pro-
vide treatment above the threshold to extend life [22].
Additionally, a consultation conducted by NICE, prior
to the implementation of the supplementary guidance,
found some support for the guidance [23]. The nature
of the support appears to relate in part to the failure of
existing evaluation methods to capture fully the value
of life-extensions for patients at the end of their life.
Significantly, the consultation also revealed concerns
regarding the lack of evidence to support the guidance
“particularly on societal preferences with respect to
end-of-life” ([24], p5). Nevertheless senior representatives
of NICE maintained a view that, “the public, generally,
places special value on treatments that prolong life – even
for a few months – at the end of life” ([25], p348). In 2014
the Scottish Medicines Consortium also introduced
changes to their procedures for end of life and very Rare
Conditions (orphan and ultra-orphan medicines) [26].
Despite a growing evidence base, in order for NICE,
SMC and others to reflect the views of the public, more
information is needed about the nature of societal values
on the subject of life-extension at the end of life. This
paper reports findings from a studyg designed to investi-
gate UK societal perspectives on the relative value of
end of life technologies.
Methods
Q methodology
Q methodology [27,28] combines qualitative and quanti-
tative methods to study ‘subjectivity’ (subjective opinions,
values or beliefs). These methods enable the identification
and description of shared views around a given topic, inthis case the relative value of life-extending treatments for
people with a terminal illness. Q studies are comprised of
two main features, a card sort used to generate data, and
factor analysis to identify patterns of similarity between
sorts. The first stage in Q studies is to derive a set of state-
ments which is representative of the conversational possi-
bilities (statements of opinion) in relation to the topic
[29]. Respondents are then guided through a card sorting
process known as a ‘Q sort’ in which they rank order the
statements onto a grid according to a condition of instruc-
tion - for example, to arrange the statements from ‘most
agree’ to ‘most disagree’. In the second stage, respondents’
Q sorts are subjected to by-person factor analysis, which
identifies underlying dimensions in the data (factors) con-
necting similar Q sorts. By averaging similar Q sorts,
factors are represented as a composite Q sort, which is
a distinctive ranking of the original set of statements
for each factor. This composite Q sort forms the basis
of interpretation, the objective of which is to produce
rich descriptions of each shared perspective (factor) on
the topic of study.
The statement set
There are two main concerns in the design of a statement
set: coverage and balance [27]. Statements should be ex-
pressions of opinion or belief (not fact) and be relevant to
the topic of study. The final set should avoid repetition
and overlap and is intended to be representative of the
population of opinions that exist in relation to the area of
study. Methods used to generate a statement set aim to
ensure that no relevant opinions are omitted. In the first
instance all that is required for a statement to be included
is that it states a subjective view on the topic in question.
In this study there were four sources of statements: the
popular media, a public consultation conducted by NICE
prior to instituting their supplementary guidance on
appraising life-extending end of life treatments, qualita-
tive interviews with key informants and focus groups
with members of the general public.
We identified a number of newspaper articles reporting
decisions of NICE committees regarding the approval or
rejection of new ‘end of life’ drugs or treatments. From
there we adopted a snowballing search strategy making
use of hyperlinks to similar newspaper and website arti-
cles. We also searched articles from specific broadsheet
and tabloid newspapers (selected to enhance the possibil-
ity of including a wide range of views) published around
the dates of NICE decisions on end of life drugs. In total
we extracted statements directly from the main text of 45
newspaper articles and from readers’ comments which
followed. The NICE public consultation in 2008 returned
over 800 statements from 300 respondents representing
different types of stakeholders [30,31]. Finally, we con-
ducted 16 interviews and three focus groups involving 20
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sample of participants with personal experience of ‘end of
life’ (for example bereaved family members, individuals
from a cancer charity, a patient group) and then targeted
individuals with relevant professional expertise; this latter
group included health and medical professionals, an aca-
demic health economist, the pharmaceutical industry and
a religious leader. Interviews followed a topic guide using
open-ended questions to elicit statements of belief and
opinion from respondents. A survey company recruited
members of the general public, based on age and sex, to
take part in focus groups. These were specifically aimed at
eliciting views felt to be underrepresented in the sample
of statements already collected, such as around reasons
for valuing end of life treatments more than other health
gains.
Examination of all sources returned more than 200
statements of belief or value related to the research ques-
tion. Statements were then categorised using topic codes.
Duplicate statements and those statements judged to be of
secondary relevance to the research question were deleted,
a process undertaken by two researchers (NMc and RB).
For example, statements related to the reallocation of re-
sources from other areas of public spending or the role of
pharmaceutical companies in drug pricing were excluded
because, although interesting, they were not directly re-
lated to the research question. Similar statements were
merged and a pilot Q set of 65 statements was reduced
further, through discussion with the wider research team
and piloting with a convenience sample of 15 respondents,
to a Q set of 49 statements (see column 2 Table 1).
Data collection
Q methodology sampling techniques are similar to those
of qualitative studies and participants are selected pur-
posively to identify data-rich respondents. Respondent
sampling does not aim to achieve representation of a
population, but rather to include those people who have
rich, strong and different views on a subject. Sampling
ceases when a ‘stable’ set of viewpoints are identified and
additional participants serve only to confirm existing
factors; typically occurring with 40–60 respondents [27].
In this study, individuals were selected who had different
types of experiences or expertise in ‘end of life’ whether
in a professional or personal capacity, who we would ex-
pect might take different positions on the subject. Thus
we targeted individuals and groups connected, but not
limited, to: academia, the pharmaceutical industry, char-
ities and patient groups, religious groups, clinicians and
people with experience of terminal illnesses (see Table 2
for a more detailed account of participants’ expertise and
experience).
As noted previously, this Q study was the first phase
of a larger project, the second phase of which is a surveydesigned on the basis of findings from phase 1. For
that reason, we also conducted the Q sort in a general
population sample, selecting 250 members of the general
public using ‘non-Q methodological’ sampling methods.
This respondent group was quota-sampled from 10 re-
gions, with a representative urban and rural split, across
the four countries of the UK. Quotas were set for age,
gender and employment status and the sample was
monitored for representation of religion, ethnicity and
self-reported health.
Each respondent completed a Q sort, administered by
a member of the research team in the ‘purposive’ sample
and a trained interviewerh in the ‘General Public’ sample.
An introduction outlined the focus of the study (see
Appendix 1) then respondents were issued with a pack of
49 shuffled statement cards (Table 1) and asked to con-
sider each statement in turn and to assign it to one of
three piles: agree, disagree, or neutral. Respondents were
then guided through the rank ordering of the statements
using the Q grid (see Figure 1). Each space in the Q grid
indicates a ranking ranging from −5 (most disagree) to +5
(most agree); all statements within a column are equally
ranked. Respondents selected two statements to place in
the two ‘most agree’ (+5) spaces on the grid, then three
statements for position +4 and then five statements for
the +3 position. Switching to the ‘disagree’ side of the Q
grid respondents followed the same process, from the left
hand side, until statements had been placed in the −5, −4
and −3 columns. Respondents completed the remaining
grid, column by column, until all 49 statements had been
positioned.
Following the completion of the Q sort there was a
short, audio-recorded interview during which respondents
were asked to sum up their views on the issues raised and
to comment on the statements placed in the extremes
of the Q grid, in positions −5 and +5. Interviews were
transcribed verbatim and transcripts stored in QSR NVivo
10 [32].
Analysis
The aim of Q factor analysis is to identify underlying
similarities between Q sorts that represent shared points
of view. Q sort data were entered into a dedicated soft-
ware package, PQMethod [33], and Centroid factor ana-
lysis was followed by Varimax rotation. Factor analysis
will usually produce several statistically possible factor
solutions. We selected the preferred factor structure
(number of factors) based on the examination of statistical
output and the coherence of accounts from the emergent
factors [27].
Interpretation of factors involves the holistic interpret-
ation and description of the perspectives represented by
the composite Q sort of each factor, with reference to
the relative position of statements within and between
Table 1 Q set and factor scores
# Statement Factors
F1 F2 F3
1 It is not worthwhile devoting more and more NHS money to someone who is going to die soon anyway 0* −5* 2*
2 We should support an individual patient's choice for treatments that give short life extensions −3* 3* −1*
3 Treatments should be directed towards people who have a greater chance of survival 3* −1* 0*
4 If a special case can be made for expensive treatments for people who are terminally ill, an equal case could be made for drugs
which slow dementia, help preserve eye sight, or reduce disability in children
3 1 2
5 At the end of their life, patients should be cared for at home with a better quality of life rather than have aggressive and
expensive treatments that will only extend life for a short period of time
4* 0* 1*
6 If somebody wants to keep fighting until the last possible moment, they should be allowed to do so, regardless of cost −4 1* −5
7 It's important to respect the wishes of patients who feel they should take every opportunity to extend their life because of
their cultural or religious beliefs
−2 1* −3
8 Patients should have the right to refuse life-extending treatments if they choose 4 5 5*
9 It is important to offer life-extending treatments to patients who have only recently found out that they are going to die soon −2* 0* −1*
10 People should accept that if it's your time to die, it's your time −1 −1 −1
11 It is important to give a dying person and their family time to prepare for their death, put their affairs in order, make peace
and say goodbyes
1* 4 3
12 I would value life extending treatments only if patients get a meaningful length of time - not just a few weeks 2* −1 −1
13 I would place more value on end-of-life treatments than many medical treatments for non-terminal conditions −4* −2 −2
14 People who will die prematurely deserve to take priority over those who have non-life-threatening illnesses, even if it's not
such a 'good' use of NHS money
−5* −1* −3*
15 Expensive drugs for people who are terminally ill and won’t benefit very much are not a good use of NHS money 2 −3* 3
16 It is human nature to want to preserve life and go on living for as long as we can - it is one of our most basic instincts −1* 3* 1*
17 If a life-extending treatment for terminally ill patients is expensive, but the only treatment available, it should still be provided −3 3* −3
18 It may not sound like much, but a few extra weeks or months might mean an awful lot to a family affected by a terminal illness 0* 4 3
19 Life should only be extended if the patient’s quality of life during that time will be good 3 1* 3
20 We all have the right to life 1* 4* −1*
21 We all pay for the NHS so we should have a right to life-extending treatment when we need it −4 2* −3
22 Real help and compassion should be about providing a death with dignity instead of more drugs to get a few more weeks or
months out of a very sick body
4 0* 4
23 A year of life is of equal value for everyone 0 0 −4*
24 You can't put a price on life 0* 3* −3*
25 We should spend proportionately more on patients when we feel those patients have not had their fair innings - in terms of
the length of their life or the quality of that life
−3* −1* 2*
26 It is wrong to raise hopes and expectations by making a special case for treatments that will only extend life by a short time 3* −2* 0*
27 To extend life in a way that is beneficial to the patient is morally the right thing to do −1 3* 0
28 If the means of helping someone live longer exists, it is morally wrong to deny them the treatment −3 1* −4
29 Not giving access to life-extending medicine to a person with a terminal illness is the same as killing them −5 −2* −5
30 The NHS budget is like a cake. Lots of small portions will do no good but if they are too big only a few people benefit.
The simple answer is not to pay for very expensive drugs which only benefit a few
1* −3 −2
31 Treatments that are very costly in relation to their health benefits should be withheld 1* −5* 3*
32 People with a diagnosis of a terminal illness know that they will die early. Other people may not know in advance that they will
die (e.g. patients with heart problems). It is unfair to give priority to those whose time of death is more likely to be known
0 −3* 1
33 End-of-life drugs are not a cure, they are life-prolonging. There is no point in delaying the inevitable for a short time 1* −4* −2*
34 Patients at the end of life will grasp any slightest hope but that is not a good reason for the NHS to provide costly treatments
that may extend life by a short time
2* −3* 4*
35 NHS provision of life-extending treatments should be decided on the basis of their cost and health benefits 5 −2* 4
36 Treatments that provide a short life extension are not worth it - they are only prolonging the pain for the patient’s family/friends −1 −4* −2
37 All human life is precious 1 5* 0
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Table 1 Q set and factor scores (Continued)
38 The health system should be about getting the greatest benefit overall for the population 5* 0 2
39 Extending life for people with terminal illness is only postponing death 0 −3* 0
40 Life is sacred and if it is possible to preserve life, every effort should be made to do so −3 1* −4
41 I wouldn’t want my life to be extended just for the sake of it - just keeping breathing is not life 3* 0* 5*
42 Treating terminally ill patients as more 'worthy' of NHS money undervalues the health of other NHS patients 2* −2* 0*
43 Everyone has a right to basic healthcare but there has to be limits and expensive, end-of-life, drugs are not basic care 2* −1* 1*
44 An end-of-life treatment which extends life-expectancy by 3 months now, is more valuable than a treatment for a long-term
illness which extends life-expectancy by 3 months in ten years time
−2* 0* 2*
45 New breakthroughs are made every day - where there’s life there’s hope −1 2* −1
46 A few weeks of extra time is more valuable when patients only have a short time left −1* 2 2
47 It's important to provide life-extending treatments to give a dying person time to reach a significant milestone, like a family
event or a personal achievement
−2* 2 1
48 I think life-extending treatments for people who are terminally ill are of less value as people get older −2* −4* 1*
49 Treating people at the end of life is not going to result in big health gains but the health system should be about looking after
those patients in greatest need
0 2 0
*denotes those statements that distinguish each factor from the other two factors (p < 0.01).
Italicized statements are consensus statements that do not distinguish between any two pairs of factors (non-significant at p > 0.01).
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which are those in the outer columns of each side of the
Q grid i.e. -5, −4, +4 or +5, and distinguishing statements,
which are those with a significantly (p < 0.01) different
position in the composite Q sort of a factor as compared
to the other factors (see Table 1). Additionally, interpret-
ation makes use of responses to the post Q sort qualitative
interviews of respondents with a high factor loading on
only one factor. These data often help to make connec-
tions, or offer explanations for why a statement is im-
portant or why the placement of two statements might
be related.
Research ethics
Ethical approval for this study was obtained from the
School of Health and Life Sciences Ethics Committee,
Glasgow Caledonian University (reference B11/04) and
the work was undertaken in line with the principles of
the Declaration of Helsinki [34]. Individuals identified as
possible participants for interviews, focus groups or Q
sorts were provided with an information document de-
scribing: the purpose and nature of the research; details
about confidentiality and storage of data; ethical approval
and funding of the project. All participants were given the
opportunity to ask further questions or to seek clarifica-
tion about any aspect of the study before deciding whether
to take part. Participants were assured that they would not
be identified in any project publications or other outputs,
informed they were free to withdraw from the study at
any time and that there were no right or wrong answers to
the questions posed. Written informed consent was pro-
vided by all interview and Q sort participants prior to data
collection. Verbal informed consent was provided by focus
group participants.Results
59 Q sorts from the ‘purposive’ sample were analysed
(see Table 3 for a summary of respondents’ characteristics).
A range of factor solutions were examined and a three
factor solution yielded interpretable accounts, which were
consistent with the qualitative data. From the ‘General
Public’ sample, factor analysis resulted in two factors
which were highly correlated with the first two factors
from the purposively sampled respondents; with correla-
tions of 0.74 and 0.92 respectively. No additional viewpoints
were identified in the general population sample and so we
focus on the more detailed results from the purposive
sample. The two viewpoints from the general popula-
tion enter our analysis as composite Q sorts – a form
of ‘meta-respondent’ (shown in Table 2 as METAGP1
and METAGP2) allowing the positioning of the three
factors together with those from the public. Thus 61 Q
sorts formed our final sample with the three factor so-
lution remaining stable.
The factors represent three different perspectives, and
all 61 Q sorts are, positively or negatively, to some greater
or lesser degree, associated with all three accounts. Factors
1 to 3 were defined by 19, 15 and 16 Q sorts, respectively
(see Tables 2 and 3 for more details). An explanation of
the rule used to indicate a defining sort follows Table 2
(for example, respondent EX044 in Table 2, helps to define
factor 1). Others do not define a factor and/or agree in
part with more than one account and are known as ‘mixed
loaders’ (for example respondent EX006).
Table 1 shows the composite Q sorts for the three factors.
The correlations between composite Q sorts were −0.05 be-
tween factors 1 and 2, 0.68 between factors 1 and 3 and
0.09 between factors 2 and 3, indicating that factors 1 and 3
are similar (the similarities and differences between these
Table 2 Respondents’ expertise/ experience and factor association
Q sort Formal expertise/association Experiential/ belief/personal F1 F2 F3
EX044 Health services research/health policy Patient family 0.81* 0.10 0.17
EX045 NHS support worker Patient/Carer of cancer patient 0.79* −0.19 0.03
EX037 General Practitioner 0.79* −0.00 0.19
EX005 Outcomes researcher/pharmaceutical industry 0.75* 0.04 0.46
EX023 Health care law/bioethics/NHS 0.75* 0.02 0.42
METAGP2 0.74* 0.14 0.39
EX033 Health economist/health policy/government 0.70* −0.20 0.42
EX054 Politician Patient family 0.70* 0.29 0.13
EX057 Journalist 0.69* −0.31 0.20
EX017 Ethics and law/academic 0.69* 0.23 0.40
EX031 Patient family 0.69* −0.15 0.26
EX040 Journalist Patient family 0.69* −0.27 0.52
EX003 Health economist/academic 0.67* −0.03 0.15
EX015 Health economist/academic 0.64* 0.21 0.55
EX034 Health policy/charity 0.62* 0.44 0.36
EX058 Pharmacy/NHS 0.62* 0.11 0.27
EX056 Pharmacist/public health/NHS 0.52* 0.13 0.47
EX052 Oncologist 0.48* 0.23 0.36
EX036 Anglican Clergyman 0.42* 0.23 0.28
METAGP1 −0.14 0.92* −0.19
EX030 Cancer survivor −0.30 0.85* −0.25
EX050 Nurse (cancer/palliative care) 0.03 0.76* 0.20
EX053 Health policy Patient family −0.18 0.72* −0.00
EX038 Journalist Patient −0.27 0.67* 0.11
EX049 Sikh/charity −0.06 0.65* −0.12
EX029 Health policy/NHS manager Patient 0.08 0.65* 0.14
EX010 Medical marketing −0.20 0.62* 0.35
EX009 Experience of bereavement 0.22 0.61* 0.14
EX032 Public health/health policy/NHS 0.25 0.60* 0.25
EX041 Chaplain/hospice 0.21 0.59* 0.24
EX042 Health policy/hospice 0.15 0.58* 0.19
EX059 Muslim 0.03 0.54* −0.17
EX022 Cancer charity/cancer nurse 0.32 0.46* 0.32
EX018 Cancer nurse 0.15 0.45* 0.39
EX024 Economist/industry −0.09 0.25 0.77*
EX014 Health economist/academic 0.37 0.30 0.68*
EX011 Health economist/academic 0.25 0.26 0.66*
EX026 Health economist/academic 0.38 −0.09 0.65*
EX055 Oncologist 0.03 0.27 0.65*
EX025 Health economist/pharmaceutical industry 0.44 −0.05 0.63*
EX001 Ethics/academic 0.27 0.10 0.63*
EX007 Health economist/NHS 0.29 0.17 0.58*
EX028 Health economist/academic 0.33 0.14 0.58*
EX021 Health economist/academic 0.30 0.10 0.54*
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Table 2 Respondents’ expertise/ experience and factor association (Continued)
EX047 Palliative medicine/charity 0.43 0.16 0.53*
EX016 Health economist/academic 0.43 0.12 0.52*
EX043 Nurse (cancer/palliative care)/charity 0.33 0.14 0.52*
EX002 Experience of bereavement/dignitas member 0.50 −0.03 0.51*
EX004 Medical ethics/academic 0.23 0.21 0.43*
EX020 Public health/health policy/NHS 0.22 0.16 0.38*
EX006 Medical advisor/pharmaceutical industry 0.33 0.34 0.45
EX008 Health technology assessment/pharmaceutical industry 0.48 0.28 0.51
EX012 Cancer research/academic 0.57 0.17 0.57
EX013 Health economist/NHS 0.59 −0.27 0.58
EX019 Health economist/academic 0.52 −0.34 0.58
EX027 Bioethics/academic 0.49 0.13 0.48
EX046 Medical consultant/palliative medicine 0.50 0.32 0.58
EX035 Health policy/charity 0.34 0.38 0.50
EX048 Nurse/health policy Patient 0.38 0.29 0.46
EX051 Cancer nurse 0.44 0.41 0.44
EX060 Muslim 0.38 0.24 −0.40
% exp. Var. 22 14 19
The significance level for factor loadings is taken as 2.58 (SE). SE represents standard error that is defined as 1/√N where N is the number of statements in the Q
set. In this case then, 2.58 (SE) = 2.58 (1/√49) = 0.37. Significant loadings are shown in bold type.
The automatic flagging procedure in PQ method software was used to identify defining sorts (*) according to the following rule: Flag loading a: if (1) a2 > h2/2
(factor ‘explains’ more than half of the common variance) and (2) a > 1.96/√(N items) (loading ‘significant at p < .05’).
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scriptions). There were two consensus (non-distinguishing)
statements across the three factors, #4 and #10.
In the following subsections each of the three factors is
described with reference to the positioning of statements
within each factor, and quotes from the post Q sort inter-
views are used to enhance both the interpretation and the
description of these accounts. Notation is used in the de-
scriptions below as follows: # indicates statement number,
and is followed by the position of that statement on the
grid for that factor. For example, (#38, +5) indicates that
statement number 38 appeared in position +5 for the
factor in question.Figure 1 Q Grid.Factor 1: A population perspective – value for money, no
special cases
Factor 1 describes a system-level perspective in which
provision of treatments and services within the National
Health Service (NHS) should aim to maximise health ben-
efits overall for the population, from the budget available,
in order to best serve the interests of society (#38, +5).
NHS resources should be allocated on the basis of the
costs of treatment in relation to the health benefits that
arise from treatment (#35, +5). Because the health system
has limited resources with multiple potential uses, value
for money is important (#15, +2; #14, −5). Hence treat-
ments that yield the greatest health improvements with
respect to cost should be prioritised. This overriding
principle implies that, aside from their capacity to benefit,
all patient groups are considered equally deserving of
treatment, no matter what their age (#48, −2), type of con-
dition (#13, −4; #14, −5, #4, +3) or ‘level of need’ (#49, 0).
“people often say . . . . . they think it’s scandalous that
something as unimportant as money should stand
between somebody in life and death, and you can
understand emotionally why that sounds right until
they stop and think about, well money isn’t just money
it’s somebody else’s opportunity for easement of pain or
suffering or prolongation of perhaps a better quality of
life” (EX040).










Age 18 - 30 4 7% 1 1 1
31 - 50 31 53% 8 6 10
51 - 64 17 29% 8 5 2
65+ 5 9% 1 2 2
Not stated 2 3% 0 0 1
Gender Female 35 59% 11 10 7
Male 24 41% 7 4 9
Expertise NHS 22 36% 8 6 5
Academic 14 24% 3 0 8
Pharmaceutical Industry 6 10% 1 1 2
Religion 5 8% 1 3 0
Patient Groups (e.g. Cancer charities) 3 5% 1 1 0
Journalist 3 5% 2 1 0
Politician 1 2% 1 0 0
Personal experience of terminal illness and/or
bereavement
5 8% 1 2 1
Experience of Terminal Illness (all
respondents)***
Cancer 30 10 10 5
Other terminal illness 23 8 8 4
No 16 4 1 8
Unstated 1 0 0 0
Note *characteristics of the general public sample defining the two ‘meta-respondents’ 60 and 61 are available from the authors on request.
**This total includes a ‘meta-respondent’ for F1 and F2 respectively. Individual characteristics for ‘meta-respondents’ are not included in this table.
***Categories within ‘Experience of Terminal Illness’ are not mutually exclusive so responses will not sum to 59.
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available budget means judging provision on the basis of
expected health gains from treatment. People with terminal
illnesses have, by definition, limited potential for health
gains, but due consideration should be given to patients
who do not have a terminal illness as well as those that do
(#42, +2). Terminal illness should not be treated as a spe-
cial case (#4, +3; #14, −5; #13, −4; #44, −2) and doing so
would imply that health gains for people with terminal
illness are valued more highly, devaluing the health of
all other NHS patients (#42, +2).
“These people do not deserve to take priority because
everybody’s got the same right to be treated…” (EX037).
Life-extending treatments, which only provide a
short life extension at high cost, should not be pro-
vided (#2, −3; #15, +2). Instead resources should be di-
rected towards other patients with a greater chance of
benefit (#6, −4; #3, +3). Prioritising life extending treat-
ments could also raise false hopes among patients who
may have high expectations of treatments that may not
deliver on meaningful health benefits (#26, +3; #34, +2)."typically people have a perception they’ll get a lot
more for using expensive drugs at the end of life than
actually the evidence suggests that they will. And
many people who talk about life extending treatment
to the end of life, possibly actually think that they’re
going to have their life saved and cured......actually it’s
pretty unclear whether it will make a difference"
(EX023).
Although an individual may have paid into the system
through their tax contributions, the NHS is a public re-
source designed to get the best overall health for the
population and people do not have a right to claim life
extending treatment particularly as these treatments are
not ‘basic care’ (#6, −4; #21; −4; #43, +2). There is no in-
herent moral requirement, in this account, to provide
treatments (#28, −3) on the basis that patients have not
had their ‘fair innings’ in life (#25, −3); or because they
have recently learned they have a short life expectancy
due to illness (#9, −2); or having no other treatments
available (#17, −3). Since the emphasis is on health bene-
fits, it also follows that life-extending treatments should
not be provided on the basis of non-health benefits,
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to enable an individual to reach a significant milestone
(#47, −2), or even because life is sacred (#40, −3).
Given that this account is focused on providing the
most cost effective treatments, other (less effective, more
costly) treatments would not be provided and hence this
population approach undermines what some patients
would regard as their individual right to access specific
treatment options - unless those treatment choices would
also maximise population health (#6, −4; #2, −3; #21, −4).
Patients do not have a choice of all possible treatments,
but across all factors there is agreement that they do have
the right to refuse treatment if they choose (#8, +4). Life
extending treatments are only of value if they are likely to
have significant health benefits to the individual such as
enhanced quality of life (#19, +3) and/or a meaningful life
extension (#12, +2; #26, +3). An individual’s wishes to have
a more comfortable and dignified end of life at home with a
better quality of life is more important than aggressive and
expensive treatments with little benefit (#22, +4; #5, +4).
Factor 2: Life is precious – valuing life-extension and
patient choice
This account is based on a belief that human life is pre-
cious, the desire to preserve life is inherent in human
nature and the impulse to go on living as long as we can
is a basic instinct (#37, +5; #16, +3). As such, everyone
should have a right to life (#20, +4) and end of life treat-
ments that result in a short life extension (and not a cure)
are worth providing (#1, −5; #33, −4; #36, −4; #49, +2)
even as people get older (#48, −4). Short life extensions for
people who are terminally ill are viewed as preserving
(#16, +3) and prolonging (#33, −4) life rather than post-
poning death (#39, −3).
From this perspective, cost effectiveness should not be
the principal basis of coverage decisions (#31, −5; #24, +3)
and just because treatments are expensive in relation to
their benefits does not, for factor 2, mean they should not
be provided (#1, −5; #34, −3; #15, −3; #35, −2).
“I think it is wrong to withhold a life prolonging
medication from someone on the basis of cost or age”
(EX050).
“…we cannot completely ignore cost but it should not
be our fundamental decision maker” (EX050).
“extending life for people with terminal illnesses is only
postponing death? Well I would say that my feelings
again are the reverse of that, that we're enhancing
what life is left” (EX029).
A key issue for factor 2 is individual patients’ choice.
Patient choice should inform resource allocation decisions(#8, +5; #2, +3). This is an account grounded in rights-
based arguments, which places the patient at the centre
(#27, +3; #20, +4; #21, +2; #16, +3). Life-extending treat-
ment should be provided if a patient wants it as everyone
has contributed to the funding of the NHS (#21, +2).
Crucially, this should apply not only to life-extending treat-
ments for terminal illness, but also to other NHS patients
with non-terminal conditions (#13, −2).
“I think that if a system such as the NHS is to be truly
compassionate, the patient choice and family choice
has to be one of the premier things that we consider”
(EX009).
Short extensions to life may be valued for the non-
health benefits to terminally ill patients or their families -
helping them to prepare for life without their loved one,
put their affairs in order, make peace, or say goodbye
(#11, +4; #36, −4; #18, +4). Life extension, if it is beneficial
to the patient, is morally the right thing to do according to
this account (#27, +3).
“if (someone wants) to achieve completion, resolution
and closure around certain issues, I believe that they
have a moral case for life-prolonging drugs” (EX038).
Factor 2 preserves hope of cure if life can be extended
for even a short period of time, here ‘where there is life
there is hope’ and the potential for new breakthroughs
(#45, +2; #26, −2).
Factor 3: Valuing wider benefits and opportunity cost – the
quality of life and death
Factor 3 is, like factor 1, an account based on concerns
about achieving value for money with respect to NHS
resources (#35, +4; #15, +3). Assessing the benefits of
treatments in relation to costs will result in denial of treat-
ments, and withholding cost-ineffective treatments is
acceptable and consistent within this account (#31, +3).
Individuals do not have a guaranteed right to be provided
with any treatment that is available (#6, −5; #21, −3) be-
cause the effective use of limited NHS resources must be
considered (# 14, −3; #35, +4; #31, +3; #34, +4).
“We should be aware of what it is costing to keep us
alive and what the cost to other people might be”
(EX002).
“it’s important that NHS resources are spent in a way
that is good value for money” (EX014).
Unlike factor 1, this account also incorporates the value
that patients and their families attach to life extension at
the end of life. Thus, treatments which extend life by a
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for money by accounting for the value placed on that
time. Such value arises from non-health benefits such
as preparing for death, making peace, spending time with
family and saying goodbye (#11, +3; #18, +3;). Time itself
could be more valuable when only a short life remains
(#46, +2; #44, +2), but treatments for patients who are ter-
minally ill are not regarded as more valuable across the
board (#13; −2; #14, −3) because quality of life and quality
of death are important (#22, +4; #19, +3). For factor 3, not
all treatments at the end of life are more valuable per se,
but some treatments, even those associated with small
health gains, may yield other benefits to patients and fam-
ilies which are of great value at the end of life. It follows
that there may be benefits that are not currently captured
in cost effectiveness analyses.
Respondents who are associated with factor 3 place great
importance on not extending life for the sake of it and pa-
tients’ right to refuse treatment (#41, +5; #8, +5), a concern
which is consistent with an emphasis on the importance of
quality of life and dignity in dying (#19, +3; #22, +4).
“we don't run society just for the aim of maximising
the person-years that can be lived and .. just because
something is technically possible, it doesn't mean that
that should be done” (EX014).
“we should think about how people die and not just
try and pretend it doesn’t happen or it’s not going to
happen” (EX011).
“death is now a huge taboo and a huge fear and so the
end of life is looked on with horror and it should not
be” (EX002).
This account holds that there are cases where more
value should be placed on time at the end of life than for
other patients, at other times (#23, −4; #44, +2; #46, +2).
However, the value of life extensions for people with a
terminal illness is not unconditional and provision
should not be based on an individual’s cultural or religious
beliefs (#7, −3) or desperate hopes (#34, +4), there must
be a worthwhile benefit (#40, −4; #15, +3), as opportunity
cost needs to be considered.
“opportunity cost matters, treating terminally ill
patients as more worthy of NHS money, undervalues
the health of other patients? Yes it does because you
have to say to somebody else, ‘we think they're more
valuable and therefore you're less valuable’” (EX026).
Discussion
The aim of this study was to identify and describe the
societal perspectives that exist around the relative valueof life-extending treatments for terminally ill patients.
The empirical literature had previously not explored quali-
tatively and in-depth the views that exist, instead studies
have been quantitative, choice based or equivalence
approaches to preference elicitation. Their equivocal find-
ings highlighted the need for more extensive qualitative
exploration to help elucidate possible reasons for dispar-
ities in quantitative findings. The three shared perspectives
found in this study highlight the plurality of views and the
importance, for both researchers and policymakers, of a
greater understanding of the issues surrounding this topic.
Discussion of the factors
Factor 1 closely resembles a utilitarian perspective. The
central principle is to achieve the greatest health gains
for the greatest number through the efficient allocation
of limited resources. People who are strongly associated
with this point of view would be unlikely to support a
policy which gave extra weight to relatively small health
gains that result from life-extending treatments at the end
of life and hence the supplementary guidance for end of
life treatments [17] would be unlikely to meet with the ap-
proval of individuals associated with factor 1.
Factor 2 is wholly different from factor 1. The utilitar-
ian tendencies of factor 1 mean that restricting the avail-
ability of cost-ineffective treatments is acceptable, whereas
factor 2 respondents reject the denial of life extending
treatments to patients with terminal illnesses. In this ac-
count patients’ rights are central and life is regarded as
precious and priceless so even high cost treatments that
deliver limited benefits should not be withheld from pa-
tients. This account is consistent in that treatments should
be provided if patients and their families feel they will be
beneficial and that patients should still be able to refuse
life-extending treatments if they choose. Yet it is unclear
whether people who align with factor 2 would support the
existence of a special policy for end of life medicines. This
is not because they believe these treatments should not
be provided but rather they appear to disagree with cost
effectiveness analysis altogether as a means of guiding
provision and oppose restriction of access to any treat-
ments for any patients who want them, regardless of
whether they are terminally ill or not.
Factor 3 appears to be a more nuanced and balanced
perspective as it supports value for money, but that value
is broader than health gains and partly defined by individ-
ual (over societal) preferences. Life-extending treatments
may be very valuable (and hence should be provided) but,
crucially, value is contingent on quality of life and life
should not be extended for the sake of it. Efficiency is an
important aspect of this account, and patients do not have
a right to any and all treatments, some of which will be
withheld on the grounds of cost effectiveness. Given the
emphasis on quality of life, it is unlikely that respondents
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NICE supplementary guidance which prioritises life-
extending treatments and does not take into account
quality of life. However they would likely support a policy
that incorporated wider benefits of value to patients and
families at the end of life. Whether that would be achieved
by weighting QALYs is not clear from this analysis alone.
A qualitative sample, such as this, does not permit gen-
eralisations about the characteristics of respondents who
are associated with each of the factors. However, interest-
ing observations can be made about the types of respond-
ent defining each factor as a potential means of enhancing
our interpretations. For example, Table 3 shows that no
academics help to define factor 2 in our sample, while fac-
tor 3 has the greatest number of academic respondents.
Of the academic respondents strongly associated with fac-
tor 3, six of the eight respondents have expertise in health
economics; two are ethicists. This does not imply that, in
general, academics or health economists will express a
view such as factor 3, but it can be brought to bear in our
interpretation of the factors. In addition, fewer factor 3 re-
spondents have had experience of a close relation or friend
suffering a terminal illness.
Ethical and policy implications
The ethical and policy implications of the accounts iden-
tified here relate, in part, to the status accorded to those
accounts – and to whether they can be considered societal
views. The factors identified, although drawn from a rela-
tively small, purposive sample of respondents, are never-
theless views that are held within society. Indeed these
views emerge from studying individuals who, we would
argue, are best placed to articulate a clear and considered
perspective on this topic given their experience or expert-
ise. This observation might explain why an additional fac-
tor was found in the purposive as compared to the general
public sample which, conversely, was quota-sampled to
reflect certain characteristics of the UK population. An
alternative or supplementary explanation for this finding
is simply that quota sampling is not an efficient way to
identify the nature of views in society, for which purpose
qualitative sampling techniques are better suited. General
population sampling methods might result in a number of
people with strong and different views on the topic of
interest, but it is equally likely not to locate those views,
unless they are strongly associated with other, particular
characteristics which happened to have entered the sam-
pling frame (for example viewpoints that strongly associ-
ate with age or ethnicity or gender).
Despite all of this, we were admittedly concerned that
we might have ‘missed something’ and so included the
general public sample as an additional ‘check’. It was re-
assuring to note that there were fewer (not more) views
discernible in the less purposeful sampling. However, themixed approach we have taken in this study raises ques-
tions about the status of the factors derived from each
sample and, in particular, whether the three factors we
describe from a sample of 59 respondents can be de-
scribed as ‘societal views’. In our view they can - since we
identified those members of society with strong and dif-
ferent views and looked for shared perspectives amongst
them. To what extent ‘society’ (i.e. a large, representative
sample of the public) supports each of the views or
how well-represented a community is by one or more
viewpoints are separate (though related) questions.
It is interesting to note that the main philosophical po-
sitions that have long dominated debates on the just al-
location of resources have a basis in public opinion. This
is most apparent in the utilitarian focus of factor 1 and
concern for the intrinsic value of life and patient rights
prominent in factor 2. Although factor 3 exhibits a greater
degree of moral pluralism, concerns with quality of life
and appropriate cost/benefit distribution also represent
ethical and economic issues that are of central importance
within policy debates.
Beyond this basic concurrence with theories, the fac-
tors present a number of challenges that need to be ad-
dressed if they are to support commitments to utilise
public opinion to inform policy and practice. Firstly, for
people associated with factor 1, end of life health gains
will never be regarded as inherently more valuable than
other treatments yielding greater health gains and compet-
ing for funding. For factor 3 the picture is less extreme
and, in the event that life extension yields real benefits
(which may or may not be related to health) and good
quality of life, the value placed on that time by patients
and their families may mean that it is good value for
money. Factor 2 gives a relatively low ranking to a
number of statements pertinent to the importance of
end of life treatment (#13, −2; #14 -1). It seems that
within factor 2 the placing of these statements is deter-
mined by that factors deference to patient choice; the
relative value of end of life treatment is determined by
whether individual patients want to avail themselves of
it – if they do, it should be provided regardless of cost.
These emergent views, taken together with other recent
empirical research, the limited support provided by NICE’s
Citizens Council and the consultation on the supplemen-
tary guidance, suggest that, if societal perspectives are a
key element in health policy decisions, further consider-
ation should be afforded to the way resources are allocated
to patients at the end of life. NICE is in the process of con-
sidering new appraisal methods (at the time of writing
these are still under consultation but include measures of
absolute and proportional QALY shortfall) which would
suggest that patients’ QALY loss in terms of both length
and quality of life could be taken into account [35]. It is
not clear whether the end of life supplementary guidance
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commitment to procedural justice it is necessary for NICE
to provide a transparent account of how public values are
incorporated into processes.
Secondly, although the factors proffer a reliable, snap
shot of the diverse ethical positions that exist amongst
the public, the perspectives do not present ready-made
policy positions. The existence of certain moral positions
does not ethically imply, and pragmatically cannot mean,
all are translated into policy. This is apparent in the di-
verse nature of often mutually exclusive standpoints and
as such ways must be found to weigh and choose between
them. Hence, it is important to know how strongly these
views are supported, and how they relate, for instance, to
political or wider social value orientations.
In addition, despite its democratic appeal, determining
policy by means of a simple majority vote could result in
policies that infringe rights and freedoms in ways that
would offend fundamental liberal sentiments [36]. A sub-
sequent ramification is that it does not necessarily follow
that because two of the three factors (and other empirical
information) are against giving greater value to end of life
treatments, that the position should be adopted. Rather,
normative judgments must be made about which views
are most appropriate in terms of ethical suitability and
viability for public policy and services. Emergent factors
can help to inform such analyses, but in order to ad-
vance critical engagement with the ethical convictions
of citizens policy makers need to engage with, and not
stand back from, the normative positions identified within
the factors.
Engagement with, and critical examination of, public
opinion is important from a public perspective to ensure
society develops in ways broadly in keeping with its fun-
damental convictions and to engender citizens with the
implications of different ethical positions, within end of
life policy and beyond. The need for this type of work
can be illustrated through a number of issues central to
debates at the end of life and within the factors; namely,
health maximisation and citizen choice. Regarding ef-
forts to maximise health gain, factor 1 represents a pos-
ition that aims to achieve the greatest overall benefits
from the limited resources that are available. In places
the factor appears to suggest that such an approach is
impartial and even-handed (#4 + 3). Thus, as Sen notes,
this type of utilitarian position has gained an “ill-deserved
egalitarian reputation” ([37], p16]). A health system based
on utilitarian principles has distributional consequences in
that it will implicitly discriminate against individuals who
will return fewer benefits from the investment of resources
obtained. Such partiality is apparent in “utilitarianism
ageism” that prioritises “the greater expected duration
of health benefits in young people that derives from
their greater life expectancy” ([38], p103); and can alsobe extended to others who can be thought of as receiving
less benefit, including the disabled or impaired [37,39] and
those with terminal illness. Difficulties emerge regarding
how to make valid judgements about the value of life to
different individuals (or sectors of the population) without
unfairly discriminating, or using assumptions that may be
flawed - such as the young will actually live longer (and so
benefit more) than those who are elderly [40].
In respect of individual choice, we have seen that fac-
tor 2 gives priority to individual rights and decisions re-
garding end of life treatment. However the factor affords
equal importance to the statements all life is precious
(#37, +5) and that patients should be able to choose to
end their lives by refusing treatment (#8, +5). Within the
ethics literature these positions do not always align easily
with each other. This is because for some people, an im-
plication of all life being precious (#37, +5) is that we
also have a basic instinct to preserve life (#16, +3).
People who hold this position are likely to see individual
decisions to refuse treatment that will end a person’s life
as being ethically unacceptable. This is because to them
choosing to end life vitiates against the idea that life is
precious. For example, within a deontological position,
with which factor 2 has much in common, there are
moral limits on patient or citizen choice. It has been ar-
gued, for example, that given the value of human life the
rationality of seeking to end such intrinsic goods may
undermine fundamental human duties [41].
Further, there exist practical limitations to support in-
dividual choice, despite factor 2’s preference for it to be
unconstrained. Namely, it is not feasible for states to
meet all needs or wants due to constrained resources. It
seems factor 2 respondents fail to acknowledge the real-
ity of budget constraints and the opportunity cost of
coverage decisions (whether explicitly stated or not) des-
pite emphasis placed on the need for health systems to
make difficult decisions about a fixed budget (see the
opening and closing paragraphs of Appendix 1). How-
ever, this ‘refusal to ration’ could be based on the belief
that the treatments would be affordable if other measures
were put in place. For example, some interview respon-
dents suggested reallocating resources from other areas
of government spending (e.g. defence), cutting waste in
the NHS, or greater regulation of pharmaceutical industry
pricing.
In liberal democracies the aim of supporting individual
freedoms through public resources makes it necessary to
achieve a balance between the public system (prioritised
by factor 1) and individual wants (privileged by factor 2);
an issue which both factor 1 and 2 overlook in favour of
ceding to their driving principle. Factor 3 however ac-
knowledges this aim in its recognition of a need for a
broader and more inclusive ‘evaluative space’. Yet, this
point of view could also prove the most challenging to
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value to patients and families at the end of life should
be considered, how they should be assessed and by
whom.
Conclusion
While this study has identified and described societal per-
spectives on the relative value of end of life technologies,
not previously explored in other empirical studies on
this issue, our findings highlight normative tensions that
require further attention. Such tensions reveal the import-
ance of critically engaging with, rather than adopting a
procedural approach to, normative issues to ensure that
public policy seeks as far as possible to promote funda-
mental convictions of society. Q methodology is an ap-
proach that can be employed to identify the issues or
tensions that need to be critically debated and deliberated.
Furthermore, for societal perspectives to be valuable for
policy it is necessary to understand the extent to which
these views are held and how they relate to specific ques-
tions of resource allocation, wider social value orientations
and other characteristics. The development of methods
to investigate these issues will be undertaken and then
employed in a nationally representative survey of the
UK general public, conducted in phase 2 of this study.
Endnotes
aThe increasing level of technology in medicine is not
the cause of this problem of scarcity, but may energise
the issue with the emergence of new and expensive phar-
maceuticals, diagnostic technologies and devices.
bExamples of such organisations are the Canadian
Agency for Drugs and Technologies in Health (CADTH);
the National Evidence-based Healthcare Collaborating
Agency (NECA) in Korea; the Health Intervention and
Technology Assessment Program (HITAP) in Thailand; the
National Health Care Institute (ZiNL) in the Netherlands;
and, in the UK - which is the context for the empirical work
reported in this paper - the National Institute for Health
and Care Excellence (NICE), the Scottish Medicines
Consortium (SMC) and the All Wales Medicines Strategy
Group (AWMSG).
cNote that ‘end of ‘life’ is often applied quite loosely in
this literature. Typically it refers to both imminent and
premature death (referring to people with a terminal ill-
ness that shortens their life expectancy and not to the
very old who reach the end of a ‘natural life span’). This
is also the context in which we use the term ‘end of life’
in this research.
dThe Citizens Council, established by NICE in 2002, is
an assembly of 30 rotating members from a variety of
backgrounds that debate and provide opinion on values-
based challenges with a bearing on the allocation of
health technologies.eQuality Adjusted Life Years (QALYs), combine mea-
sured changes in the quality and quantity of life and are
used to assess the health benefits of treatments. The
findings of cost-utility analyses are typically presented in
terms of the cost per QALY gained. NICE apply a cost-
effectiveness threshold (range) of £20,000-£30,000 per
QALY gained, above which technologies are usually not
recommended for NHS funding unless a special case is
made for their provision [25,42].
fThis includes, but is not limited to, the public, patients,
NHS managers, healthcare professionals and the pharma-
ceutical industry.
gThis study was funded by the Medical Research
Council Methodology Panel and represents the first stage
of a two-part study. In this phase of work we applied
established methods (Q methodology), in the second
phase we explored different survey methods to investi-
gate the prevalence and distribution of the societal
perspectives identified and reported here.
hA survey company (IPSOS MORI) were commissioned
to conduct the 250 Q sorts with the general public. Inter-
viewers were trained by the research team to adminis-
ter the Q sorts and also observed Q sorts with pilot
respondents.Appendix 1 Introduction
The National Health Service only has so much money
available. There are many things that the NHS could
spend the money on like new drugs, treatments, doctors,
nurses, beds and so on. Unfortunately not everything can
be funded, no matter how large the budget.
You may have views about other government spend-
ing – but this study is concerned with how the health
budget is spent, so we’d like you to focus on that.
These are difficult decisions. The cost of each treat-
ment and how much good it does have to be considered,
as do views about what else might count when deciding
how to ‘cut the NHS cake’ - for example, whether to
spend money treating those people who are the most se-
verely ill; or favouring treatments that give patients a
better quality of life; or else treatments that help them
live longer.
It is important that the general public has a say as they
pay the bills, benefit from the services provided and do
not benefit if a service is not provided.
In this project, we are interested in what you think
about funding treatments that help terminally ill patients
to live longer.
These treatments will not cure their illness, but they
will extend their life, usually by weeks or months. These
treatments have to be paid for and if money is spent on
these treatments it would not then be available to spend
elsewhere in the NHS.
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